AR062927A1 - 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada - Google Patents
4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratadaInfo
- Publication number
- AR062927A1 AR062927A1 ARP070104168A ARP070104168A AR062927A1 AR 062927 A1 AR062927 A1 AR 062927A1 AR P070104168 A ARP070104168 A AR P070104168A AR P070104168 A ARP070104168 A AR P070104168A AR 062927 A1 AR062927 A1 AR 062927A1
- Authority
- AR
- Argentina
- Prior art keywords
- fluorophenoxy
- phenyl
- amino
- carboxamide
- monohidrated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Abstract
La presente refiere a 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil)amino)-3-fluorofenoxi]-N-metilpiridin-2-carboxamida monohidratada, a procedimientos para su preparacion, a composiciones farmacéuticas que la comprenden y a su uso en el control de trastornos Reivindicacion 2: El compuesto de la reivindicacion 1 que muestra en la difractometría de rayos X un pico máximo de ángulo 2 theta de 21,2. Reivindicacion 3: El compuesto de la reivindicacion 1 que muestra en el espectro FIR un pico máximo de 353 cm-1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06021296 | 2006-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062927A1 true AR062927A1 (es) | 2008-12-17 |
Family
ID=38972960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104168A AR062927A1 (es) | 2006-10-11 | 2007-09-20 | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
Country Status (38)
Country | Link |
---|---|
US (3) | US9957232B2 (es) |
EP (1) | EP2097381B1 (es) |
JP (1) | JP5346293B2 (es) |
KR (1) | KR101418623B1 (es) |
CN (1) | CN101547903B (es) |
AR (1) | AR062927A1 (es) |
AU (1) | AU2007306716B2 (es) |
BR (1) | BRPI0719828B1 (es) |
CA (1) | CA2666170C (es) |
CL (1) | CL2007002930A1 (es) |
CO (1) | CO6150132A2 (es) |
CR (1) | CR10663A (es) |
CY (1) | CY1114637T1 (es) |
DK (1) | DK2097381T3 (es) |
ES (1) | ES2427358T3 (es) |
GT (1) | GT200900057A (es) |
HK (1) | HK1136287A1 (es) |
HN (1) | HN2009000499A (es) |
IL (1) | IL197369A (es) |
JO (1) | JO3021B1 (es) |
MA (1) | MA30878B1 (es) |
MX (1) | MX2009002642A (es) |
MY (1) | MY152595A (es) |
NZ (1) | NZ576153A (es) |
PA (1) | PA8750301A1 (es) |
PE (1) | PE20081459A1 (es) |
PL (1) | PL2097381T3 (es) |
PT (1) | PT2097381E (es) |
RU (1) | RU2466992C2 (es) |
SG (1) | SG175584A1 (es) |
SI (1) | SI2097381T1 (es) |
SV (1) | SV2009003187A (es) |
TN (1) | TN2009000072A1 (es) |
TW (1) | TWI428322B (es) |
UA (1) | UA95984C2 (es) |
UY (1) | UY30633A1 (es) |
WO (1) | WO2008043446A1 (es) |
ZA (1) | ZA200902469B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1626714E (pt) * | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
SI1663978T1 (sl) | 2003-07-23 | 2008-02-29 | Bayer Pharmaceuticals Corp | Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj |
DK1797038T3 (da) * | 2004-09-29 | 2012-09-03 | Bayer Pharma AG | Termodynamisk stabil form af bay 43-9006-tosylat |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
WO2008058644A1 (en) * | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
AU2015201426B2 (en) * | 2010-04-15 | 2016-07-07 | Bayer Healthcare Llc | Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
CN103228274A (zh) | 2010-10-01 | 2013-07-31 | 拜耳知识产权有限责任公司 | 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合 |
US20140296301A1 (en) | 2011-06-28 | 2014-10-02 | Bayer Pharma Aktiengesellschaft | Topical ophthalmological pharmaceutical composition containing regoragenib |
JO3479B1 (ar) | 2012-09-06 | 2020-07-05 | Bayer Healthcare Llc | تركيبة دوائية مغلفة تحتوي على ريجورافنيب |
MX357035B (es) | 2012-09-25 | 2018-06-25 | Bayer Pharma AG | Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer. |
UY35183A (es) | 2012-12-21 | 2014-07-31 | Bayer Healthcare Llc | Composición farmacéutica oftalmológica tópica que contiene regorafenib |
US9518020B2 (en) * | 2013-10-04 | 2016-12-13 | Hetero Research Foundation | Process for Regorafenib |
CN103923000A (zh) * | 2014-01-29 | 2014-07-16 | 苏州晶云药物科技有限公司 | 几种新晶型及其制备方法 |
CN103923001B (zh) * | 2014-04-30 | 2016-02-10 | 药源药物化学(上海)有限公司 | 瑞戈非尼盐及其晶型、制备方法 |
WO2016005874A1 (en) | 2014-07-09 | 2016-01-14 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
WO2016038590A1 (en) | 2014-09-12 | 2016-03-17 | Mylan Laboratories Ltd | Process for the preparation of crystalline form i of regorafenib |
CN104546776B (zh) * | 2015-02-10 | 2017-08-22 | 杭州朱养心药业有限公司 | 瑞戈非尼片剂药物组合物和制法 |
CN105985287B (zh) * | 2015-02-13 | 2018-07-17 | 上海京新生物医药有限公司 | 一种瑞戈非尼新晶型 |
CN107118153A (zh) * | 2016-02-25 | 2017-09-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种瑞戈非尼一水合物晶型及其制备方法 |
CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
CN110662540B (zh) | 2017-06-02 | 2024-01-26 | 拜耳医药保健有限责任公司 | 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品 |
EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
WO2021160708A1 (en) | 2020-02-14 | 2021-08-19 | Bayer Aktiengesellschaft | Combination of regorafenib and msln-ttc for treating cancer |
CN111995571B (zh) * | 2020-08-07 | 2021-12-03 | 天津理工大学 | 一种瑞戈非尼与马来酸的共晶及其制备方法 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6705789A (es) | 1967-03-08 | 1968-09-09 | ||
US4223153A (en) | 1979-02-09 | 1980-09-16 | Eli Lilly And Company | Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
NZ220764A (en) | 1986-07-02 | 1989-09-27 | Shionogi & Co | Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions |
US4835180A (en) | 1986-10-02 | 1989-05-30 | Sterling Drug Inc. | N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5629425A (en) | 1994-09-19 | 1997-05-13 | Eli Lilly And Company | Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene |
CO4410190A1 (es) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO |
WO1997046526A1 (en) | 1996-06-07 | 1997-12-11 | Eisai Co., Ltd. | Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production |
ID21924A (id) | 1996-09-23 | 1999-08-12 | Lilly Co Eli | Olanzapin dihidrat d |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US6344476B1 (en) | 1997-05-23 | 2002-02-05 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US20120046290A1 (en) | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
US20080269265A1 (en) | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
IN190389B (es) | 1999-07-14 | 2003-07-26 | Ranbaxy Lab Ltd | |
WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
MEP36208A (en) | 2001-12-03 | 2011-02-10 | Bayer Corp | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
US20030207872A1 (en) | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20080108672A1 (en) | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
US7928277B1 (en) | 2002-02-11 | 2011-04-19 | Cox Jr Henry Wilmore | Method for reducing contamination |
ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
MXPA04010778A (es) | 2002-05-03 | 2005-03-07 | Janssen Pharmaceutica Nv | Microemulsiones polimericas. |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
WO2006125540A1 (en) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment |
SI1663978T1 (sl) * | 2003-07-23 | 2008-02-29 | Bayer Pharmaceuticals Corp | Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj |
EP1678123A1 (en) | 2003-10-15 | 2006-07-12 | Bayer HealthCare AG | Tetrahydro-naphthalene and urea derivatives |
TWI338004B (en) | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
CA2578442A1 (en) | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | Pharmaceutical compositions comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide for the treatment of cancer |
US8124782B2 (en) | 2004-09-29 | 2012-02-28 | Bayer Pharma Aktiengesellschaft | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide |
DK1797038T3 (da) | 2004-09-29 | 2012-09-03 | Bayer Pharma AG | Termodynamisk stabil form af bay 43-9006-tosylat |
CA2601955C (en) | 2005-03-07 | 2012-07-10 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
JP2008545670A (ja) | 2005-05-27 | 2008-12-18 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 疾患を処置するためのジアリールウレア類を含む組合せ治療 |
BRPI0617488A2 (pt) | 2005-10-21 | 2011-07-26 | Bayer Healthcare Llc | mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente |
US8329408B2 (en) | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
US20090215835A1 (en) | 2005-10-31 | 2009-08-27 | Scott Wilhelm | Treatment of cancer with sorafenib |
CA2627875A1 (en) | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Combinations comprising sorafenib and interferon for the treatment of cancer |
KR20080073729A (ko) | 2005-11-02 | 2008-08-11 | 바이엘 헬스케어 엘엘씨 | 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법 |
MY144860A (en) | 2005-11-10 | 2011-11-30 | Bayer Schering Pharma Ag | Diaryl ureas for treating pulmonary hypertension |
US20100035888A1 (en) | 2005-11-10 | 2010-02-11 | Bater Healthcare AG | Diaryl Urea for Treating Pulmonary Hypertension |
WO2007059094A2 (en) | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
WO2007059154A2 (en) | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2007064872A2 (en) | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Urea compounds useful in the treatment of cancer |
US20090227637A1 (en) | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
WO2007068380A1 (en) | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl urea for treating virus infections |
CA2633417A1 (en) | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl ureas for treating virus infections |
EP1973897B1 (en) | 2005-12-21 | 2014-05-21 | Bayer Intellectual Property GmbH | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
WO2007139930A2 (en) | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
CA2668748A1 (en) | 2006-11-09 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
WO2008058644A1 (en) | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
WO2008079968A1 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
JP2010514692A (ja) | 2006-12-20 | 2010-05-06 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物 |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2008089388A2 (en) | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
US8217061B2 (en) | 2008-01-17 | 2012-07-10 | Sicor Inc. | Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof |
EP2296641A1 (en) | 2008-06-25 | 2011-03-23 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
JP5439494B2 (ja) | 2008-10-21 | 2014-03-12 | バイエル ヘルスケア エルエルシー | 肝細胞癌と関連するシグネチャ遺伝子の同定 |
CA2775296A1 (en) | 2009-09-24 | 2011-03-31 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
EP2499116A1 (en) | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
WO2011146725A1 (en) | 2010-05-19 | 2011-11-24 | Bayer Healthcare Llc | Biomarkers for a multikinase inhibitor |
JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
-
2007
- 2007-09-20 AR ARP070104168A patent/AR062927A1/es unknown
- 2007-09-29 US US12/444,974 patent/US9957232B2/en active Active
- 2007-09-29 RU RU2009117388/04A patent/RU2466992C2/ru active
- 2007-09-29 EP EP07818583.2A patent/EP2097381B1/en active Active
- 2007-09-29 MX MX2009002642A patent/MX2009002642A/es active IP Right Grant
- 2007-09-29 UA UAA200904623A patent/UA95984C2/ru unknown
- 2007-09-29 BR BRPI0719828-0A patent/BRPI0719828B1/pt active IP Right Grant
- 2007-09-29 CN CN200780037680.2A patent/CN101547903B/zh active Active
- 2007-09-29 PT PT78185832T patent/PT2097381E/pt unknown
- 2007-09-29 AU AU2007306716A patent/AU2007306716B2/en active Active
- 2007-09-29 JP JP2009531733A patent/JP5346293B2/ja active Active
- 2007-09-29 DK DK07818583.2T patent/DK2097381T3/da active
- 2007-09-29 PL PL07818583T patent/PL2097381T3/pl unknown
- 2007-09-29 WO PCT/EP2007/008503 patent/WO2008043446A1/en active Application Filing
- 2007-09-29 SG SG2011071990A patent/SG175584A1/en unknown
- 2007-09-29 SI SI200731313T patent/SI2097381T1/sl unknown
- 2007-09-29 ES ES07818583T patent/ES2427358T3/es active Active
- 2007-09-29 CA CA2666170A patent/CA2666170C/en active Active
- 2007-09-29 NZ NZ576153A patent/NZ576153A/en unknown
- 2007-09-29 KR KR1020097007422A patent/KR101418623B1/ko active IP Right Review Request
- 2007-09-29 MY MYPI20091350 patent/MY152595A/en unknown
- 2007-10-07 JO JOP/2007/0423A patent/JO3021B1/ar active
- 2007-10-08 UY UY30633A patent/UY30633A1/es not_active Application Discontinuation
- 2007-10-09 TW TW096137745A patent/TWI428322B/zh active
- 2007-10-10 PA PA20078750301A patent/PA8750301A1/es unknown
- 2007-10-10 PE PE2007001368A patent/PE20081459A1/es not_active Application Discontinuation
- 2007-10-11 CL CL200702930A patent/CL2007002930A1/es unknown
-
2009
- 2009-02-27 TN TN2009000072A patent/TN2009000072A1/fr unknown
- 2009-03-03 IL IL197369A patent/IL197369A/en active IP Right Grant
- 2009-03-11 CO CO09025191A patent/CO6150132A2/es unknown
- 2009-03-12 GT GT200900057A patent/GT200900057A/es unknown
- 2009-03-13 CR CR10663A patent/CR10663A/es unknown
- 2009-03-13 SV SV2009003187A patent/SV2009003187A/es unknown
- 2009-03-18 HN HN2009000499A patent/HN2009000499A/es unknown
- 2009-04-09 ZA ZA200902469A patent/ZA200902469B/xx unknown
- 2009-05-08 MA MA31857A patent/MA30878B1/fr unknown
-
2010
- 2010-03-24 HK HK10103082.1A patent/HK1136287A1/xx unknown
-
2013
- 2013-09-16 CY CY20131100798T patent/CY1114637T1/el unknown
-
2014
- 2014-05-14 US US14/277,095 patent/US20140315958A1/en not_active Abandoned
-
2018
- 2018-01-30 US US15/884,103 patent/US20180194730A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062927A1 (es) | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada | |
ECSP077356A (es) | Forma termodinámicamente estable de una sal tosilato | |
CY1109842T1 (el) | Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i | |
CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
BRPI0607015A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
BRPI0715893A2 (pt) | composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono | |
BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
ATE440833T1 (de) | Antithrombotische diamide | |
UY28774A1 (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes. | |
ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
CL2007002479A1 (es) | Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos. | |
WO2008087182A3 (de) | Fungizide mischungen aus 1-methylpyrazol-4-ylcarbonsäureaniliden und azolopyrimidinylaminen | |
WO2009126861A3 (en) | Triazolopyridine compounds useful as dgat1 inhibitors | |
DK2076502T3 (da) | Substituerede carboxamider som antagonister af gruppe-1 metabotrope receptorer | |
WO2009076399A3 (en) | Aminotetralin compounds as mu opioid receptor antagonists | |
NO20073702L (no) | Ikke-steroid glukocorticoid reseptor modulatorer | |
WO2009148600A3 (en) | Deuterated lysine-based compounds | |
CO6390054A2 (es) | Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina | |
EA201000611A1 (ru) | 4,4-дизамещенные пиперидины | |
EA200701180A1 (ru) | Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств | |
CL2007002366A1 (es) | Sales maleato, tosilato, fumarato y oxalato de 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida; proceso de preparacion de dichas sales, utiles para el tratamiento de afecciones | |
EA201000720A1 (ru) | 4,4-дизамещённые пиперидины как ингибиторы ренина | |
TH98396B (th) | 4-[4-({[4-cคลอโร-3-(ไตรฟลูออโรเมทธิล) ฟีนิล]คาร์บาโมอิล}อะมิโน)-3-ฟลูออโรฟีนอกซี]-n-เมทธิลไพริดีน-2-คาร์บอกซาไมด์ โมโนไฮเดรท | |
DOP2005000184A (es) | Forma termodinamicamente estable de una sal tosilato |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |